Navigation Links
Medizone International Takes Aim at the Bioterrorism Countermeasures Arena
Date:12/1/2009

SAN FRANCISCO, Dec. 1 /PRNewswire-FirstCall/ -- Medizone International, Inc. (OTC Bulletin Board: MZEI) announced today that in tests involving its proprietary AsepticSure(TM) technology, it continues to break "6 log" decontamination barriers, this time with two very different spore forming bacteria, Claustridium difficile and Bacillis subtilis. These results clearly establish AsepticSure(TM) as an extremely potent sporicidal technology. "The implications of a 6.7 log reduction (99.99997 %) in C difficile are indeed significant for the entire health care system," stated Dr Michael Shannon, Director of Medical Affairs for Medizone. "However, even though our findings for Bicillis subtilis are preliminary, the potential of being able to eliminate 99.999992% (7.2 log kill) of an internationally accepted surrogate for Anthrax in 90 minutes will have national security implications." In response to this news, Mr. Brad Goble, CEO of TDV GLOBAL and a Canadian leader in global health security and bio-terrorism countermeasures commented, "The international community continues to strengthen collaboration in the area of medical countermeasures, including placing a high priority on new and emerging technologies for decontamination. Medizone's early laboratory results with Bicillis subtilis will attract great interest from the global defense and public health portfolios alike." Medizone believes that a field hardened variant of the AsepticSure(TM) hospital unit currently being readied for scale up testing will have wide bio defense applications internationally as it will be easily deployable in response to virtually any terrorist assault, extremely effective against a broad range of lethal pathogens, easy to manage and maintain and most importantly, it has the potential to save lives.

Medizone's CEO Edwin Marshall added, "Following the impressive results recently announced for MRSA, we immediately began to assess the capability of AsepticSure(TM) using the same updated technology with the spore forming bacteria C difficile, which is ubiquitous within hospitals and chronic care centers. Following those results we then worked with Bicillis subtilis, which represents the infamous and highly lethal terrorist agent, Anthrax. In both cases, these two pathogens remain very resistant to standard decontamination procedures and hence, seeing our technology virtually annihilate these two difficult spore formers has lead Medizone to a parallel track of development with its AsepticSure(TM) technology which we are convinced will open up the possibility for commercialization in both arenas."

Medizone International, Inc., is a research and development company engaged in developing its AsepticSure(TM) technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. Medizone's dedicated research laboratory located in Innovation Park at Queen's University in Kingston, Ontario, Canada is currently being doubled in size to accommodate full scale room testing of the AsepticSure(TM) system. Construction and full instrumentation of the expanded facility is expected to be completed over the next two weeks.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.


       Investor Relations: 415-868-0300 / web site: www.medizoneint.com
                     E-mail: operations @ medizoneint.com

SOURCE Medizone International, Inc.


'/>"/>
SOURCE Medizone International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medizone International, Inc. Announces Establishment of Canadian Foundation for Global Health
2. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
3. Mercy Ships and MediSend International Partner to Deliver Hope and Healing
4. French Ambassador for International Investment to Visit Toronto December 11
5. French Ambassador for International Investment to Visit Chicago December 9 and 10
6. Wyle Personnel Take Part in Important Studies Aboard the International Space Station
7. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
8. Advanced Cell Technologys Chief Scientific Officer, Robert Lanza, Opening Plenary Speaker at the 3rd International Conference on Cell Therapy
9. Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results
10. Daval International Awarded Orphan Drug Designation for Motor Neurone Disease Treatment
11. Microfluidics International Corporation Announces Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
(Date:10/11/2017)... ... , ... Disappearing forests and increased emissions are the main causes of the ... Especially those living in larger cities are affected by air pollution related diseases. , ... pollution-affected countries globally - decided to take action. , “I knew I had to ...
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
Breaking Biology Technology:
(Date:5/23/2017)... , May 23, 2017  Hunova, the first robotic gym for the ... been officially launched in Genoa, Italy . The first ... and the USA . The technology was developed ... market by the IIT spin-off Movendo Technology thanks to a 10 million ... News Release, please click: ...
(Date:5/6/2017)... SINGAPORE , May 5, 2017 ... has just announced a new breakthrough in biometric ... that exploits quantum mechanical properties to perform ... new smart semiconductor material created by Ram Group ... across finance, entertainment, transportation, supply chains and security. ...
(Date:4/18/2017)... Calif. , April 18, 2017  Socionext Inc., a global ... of a media edge server, the M820, which features the company,s ... recognition software provided by Tera Probe, Inc., will be showcased during ... at the NAB show at the Las Vegas ... ...
Breaking Biology News(10 mins):